COVID-19 vaccine induced interstitial lung disease

Ayumi Yoshifuji; Kota Ishioka; Yuya Masuzawa; Shuntaro Suda; Saori Murata; Yoshifumi Uwamino; Motoko Fujino; Hiromi Miyahara; Naoki Hasegawa; Munekazu Ryuzaki; Haruhiko Hoshino; Kazuhiko Sekine

doi:10.1016/j.jiac.2021.09.010

COVID-19 vaccine induced interstitial lung disease

Ayumi Yoshifuji, Kota Ishioka, Yuya Masuzawa, Shuntaro Suda, Saori Murata, Yoshifumi Uwamino, Motoko Fujino, Hiromi Miyahara, Naoki Hasegawa, Munekazu Ryuzaki, Haruhiko Hoshino, Kazuhiko Sekine

研究成果: Article › 査読

19 被引用数 (Scopus)

抄録

A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.

本文言語	English
ページ（範囲）	95-98
ページ数	4
ジャーナル	Journal of Infection and Chemotherapy
巻	28
号	1
DOI	https://doi.org/10.1016/j.jiac.2021.09.010
出版ステータス	Published - 2022 1月

ASJC Scopus subject areas

微生物学（医療）
感染症
薬理学（医学）

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/j.jiac.2021.09.010

他のファイルとリンク

引用スタイル

@article{6563f551ea5a427ebfd314c5a8f5cd99,

title = "COVID-19 vaccine induced interstitial lung disease",

abstract = "A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.",

keywords = "Adverse events, COVID-19 vaccine, Drug-induced interstitial lung disease",

author = "Ayumi Yoshifuji and Kota Ishioka and Yuya Masuzawa and Shuntaro Suda and Saori Murata and Yoshifumi Uwamino and Motoko Fujino and Hiromi Miyahara and Naoki Hasegawa and Munekazu Ryuzaki and Haruhiko Hoshino and Kazuhiko Sekine",

note = "Publisher Copyright: {\textcopyright} 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases",

year = "2022",

month = jan,

doi = "10.1016/j.jiac.2021.09.010",

language = "English",

volume = "28",

pages = "95--98",

journal = "Journal of Infection and Chemotherapy",

issn = "1341-321X",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - COVID-19 vaccine induced interstitial lung disease

AU - Yoshifuji, Ayumi

AU - Ishioka, Kota

AU - Masuzawa, Yuya

AU - Suda, Shuntaro

AU - Murata, Saori

AU - Uwamino, Yoshifumi

AU - Fujino, Motoko

AU - Miyahara, Hiromi

AU - Hasegawa, Naoki

AU - Ryuzaki, Munekazu

AU - Hoshino, Haruhiko

AU - Sekine, Kazuhiko

PY - 2022/1

Y1 - 2022/1

N2 - A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.

AB - A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.

KW - Adverse events

KW - COVID-19 vaccine

KW - Drug-induced interstitial lung disease

UR - http://www.scopus.com/inward/record.url?scp=85115965498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115965498&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2021.09.010

DO - 10.1016/j.jiac.2021.09.010

M3 - Article

C2 - 34580010

AN - SCOPUS:85115965498

SN - 1341-321X

VL - 28

SP - 95

EP - 98

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

IS - 1

ER -

COVID-19 vaccine induced interstitial lung disease

抄録

ASJC Scopus subject areas

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル